The startup develops diagnostic tools focused on biomarker discovery for infectious, liver, and kidney diseases, utilizing advanced analytical methods to enhance early detection. Their reliable and affordable diagnostics enable patients to identify these conditions promptly, improving treatment outcomes and reducing healthcare costs.
Funding
$900K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current diagnostic methods for infectious diseases, liver conditions, and kidney ailments often lack the sensitivity for early detection, leading to delayed treatment and poorer patient outcomes. Traditional diagnostic processes can also be time-consuming and costly, hindering timely intervention and effective disease management. The rise of antimicrobial resistance (AMR) further complicates the accurate differentiation between bacterial and viral infections, contributing to the overuse of antibiotics.
Solution
Levels Diagnostics is developing a suite of rapid, point-of-care diagnostic tests for early detection and differentiation of infectious, liver, and kidney diseases. The company employs advanced proteomic screening and statistical analysis to identify novel biomarker combinations. These biomarkers are then integrated into microfluidics or lateral flow assays, enabling rapid results at the point of care. Levels Diagnostics focuses on improving diagnostic accuracy for conditions like hepatocellular carcinoma (HCC) and differentiating between bacterial and viral respiratory infections to combat antimicrobial resistance.
Target Audience
The primary target audience includes healthcare providers, hospitals, and diagnostic laboratories seeking rapid and accurate diagnostic tools for infectious diseases, liver conditions, and kidney ailments.
Features
- Identification of proprietary biomarker panels for early-stage detection of hepatocellular carcinoma (HCC)
- Development of rapid diagnostic tests to differentiate between bacterial and viral respiratory infections
- Discovery studies to identify biomarkers for predicting the onset of sepsis
- Clinical trial design and execution for biomarker validation
- State-of-the-art proteomic screening for biomarker discovery
- Development of point-of-care rapid diagnostic tests (e.g., microfluidics or lateral flow assays)